Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CathVision Cube

Financiado

Cerrado

CathVision Cube disruptive data driven guidance for successful cardiac ablation...

CathVision Cube disruptive data driven guidance for successful cardiac ablation therapy Cardiac arrhythmias are projected to rise during next years. The most prevalent type, Atrial Fibrillation, is projected to increase in the EU from 8.8m in 2010 to 17.9m by the year 2060, leading to a strain on physicians and healt... ver más

31/07/2021

CATHVISION

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

CATHVISION APS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-07-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 69% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

CATHVISION

2.18M€ | Lider

DISENOS Y DESARROLLOS ATTA S...

209.66K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PTQ2023-012972 GEMINIS - AI-Enhanced Global Cardiac Mapping with Electrocar... 114K€ Cerrado

PID2020-119364RB-I00 DESARROLLO DE UNA HERRAMIENTA DE MAPEO PANORAMICO PARA LA EV... 195K€ Cerrado

DPI2017-83952-C3-1-R ESTUDIO MULTICENTRICO PARA LA EVALUACION DEL SUSTRATO ARRITM... 157K€ Cerrado

Neuron-AFib Commercialising cardiac autonomic modulation to treat Atrial... 3M€ Cerrado

TEC2010-20633 DESARROLLO Y APLICACION DE ESTIMADORES AVANZADOS DE ORGANIZA... 207K€ Cerrado

Duración del proyecto: 23 meses Fecha Inicio: 2019-08-13
Fecha Fin: 2021-07-31

Líder del proyecto

CATHVISION APS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cardiac arrhythmias are projected to rise during next years. The most prevalent type, Atrial Fibrillation, is projected to increase in the EU from 8.8m in 2010 to 17.9m by the year 2060, leading to a strain on physicians and health systems. Thus, better ablation guiding tools will be necessary to help physicians more efficiently identify, characterise and treat arrhythmias, facilitating training of new electrophysiologists, while reducing procedure and medicine costs. Sex-specific CVD also needs to be better addressed, as it is currently often misdiagnosed in females due to smaller cardiac signals and standards based on male physiology. CathVision Cube is a low-noise electrophysiology (EP) recording system that combines a cutting-edge amplifier with AI assisted decision-making and easy-to-use user interface. Physicians will have access to exceptional EP signals thanks to proprietary hardware technology that reduces noise, prevents signal artefacts and improves signal quality. Doctors will also gain electrogram-driven clinical decision support through the intuitive and logical graphical interface of our AI-software, which allows proper identification of arrhythmogenic areas and guidance to a successful ablation – particularly important for less experienced EP physicians. Moreover, our system enables data export to Electronic Medical Records (EMR), integrates seamlessly into the hospital environment and is also compatible with third-party equipment. Our goal is to mature, pilot and commercialise our CathVision Cube – the world first low-noise EP recording system and AI-assisted decision-making for physicians performing cardiac ablation therapy. A successful CathVision Cube project will create measurable impacts on our company, quantified as accumulated revenue of €457m in 5 years (2021-2025), accumulated operating profit of €348m, creating 45 FTE in our value chain, generating €1.35m in reduced annual costs per hospital and unlocking public savings of €1.1bn by 2025

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores